“Vascular endothelial growth factor (VEGF)” has been linked to the development of diabetic retinopathy in earlier studies (DR). Although numerous research has examined the efficacy of “anti-VEGF for diabetic macular oedema”, proliferative diabetic retinopathy has received less attention (PDR). This study is a review of pertinent works on the application of antiVEGF to the management of PDR. “Systematic searches of PUBMED and the Cochrane Central Register of Controlled Trials” yielded the articles. We examined the strength of the scientific literature's evidence at the conclusion of each section. Anti-VEGF medications used off-label were proven to be helpful in PDR, particularly in situations of chronic vitreous haemorrhage, neovascular glaucoma, and preceding vitrectomy. The use of “anti-VEGF” has drawbacks including short effect duration, rare occurrences of endophthalmitis, and tractional retinal detachment in cases with pre-existing pre-retinal fibrosis. Large randomised trials have not provided conclusive proof of the “effectiveness of anti-VEGF therapy in PDR”. However, a number of case studies, a strong biochemical mechanism of action, and growing knowledge about the use of anti-VEGF medications can be utilised to support the continued use of this therapeutic approach in some patients.